Disease of the liver: Acute liver disease

Hospital Pharmacist

Volumn 9, Issue 5, 2002, Pages 131-136

  Richardson, Paul ^a   O'Grady, John G ^a  

^a Department of Accident and Emergency   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ACETYLCYSTEINE; ADRENALIN; ALLOPURINOL; ANTIBIOTIC AGENT; BARBITURIC ACID; CARBAMAZEPINE; DOBUTAMINE; DOPAMINE; ENFLURANE; FLUTAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HALOTHANE; INDOMETACIN; INOTROPIC AGENT; ISOFLURANE; ISONIAZID; KETOCONAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; OCTREOTIDE; PARACETAMOL; PHENYTOIN; PROSTAGLANDIN SYNTHASE INHIBITOR; RIFAMPICIN; SULFONAMIDE; TERLIPRESSIN; TETRACYCLINE; UNINDEXED DRUG; VALPROIC ACID;

ACUTE DISEASE; ANTIBIOTIC PROPHYLAXIS; BRAIN EDEMA; DISEASE CLASSIFICATION; HEMODYNAMIC MONITORING; HEPATORENAL SYNDROME; HUMAN; KIDNEY FAILURE; LIVER DISEASE; LIVER TRANSPLANTATION; NUTRITIONAL DEFICIENCY; PATIENT MONITORING; REVIEW; SEPSIS;

EID: 0036262968     PISSN: 13527967     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. The management of fulminant hepatic failure
2. Acute liver failure: Redefining the syndromes
3. Acute liver failure: Results of a 5-year clinical protocol
4. Etiology and outcome for 295 patients with acute liver failure in the United States
5. Intravenous acetyleysteine in paracecamol-induced fulminant hepatic failure: A prospective controlled trial
6. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985)
7. Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine
8. Effects of legislation restricting pack sizes of paracetamol and salicylate on self poisoning in the United Kingdom; before and after study
9. Intensive care management of patients with acute liver failure with emphasis on systemic hemodynamic instability and cerebral edema: A critical appraisal of pathophysiology
10. Cerebral perfusion, cardiac output, and arterial pressure in patients with fulminant hepatic failure
11. Tissue hypoxia during fulminant hepatic failure
12. Lactic acidosis in fulminant hepatic failure. Some aspects ofpathogenesis and prognosis
13. Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: A systematic review of randomised trials
14. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure
15. Early indicators of prognosis in fulminant hepatic failure
16. Fulminant and subfulminant liver failure: Definitions and causes
17. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure
18. Liver assist systems: State of the art
19. Earlier charcoal haemoperfusion in fulminant: Hepatic failure
20. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure
21. High-volume plasmapheresis and acute liver transplantation in fulminant hepatic failure
22. Effects of high-volume plasmapheresis on ammonia, urea, and amino acids in patients with acute liver failure
23. Role of plasmapheresis in the management of acute hepatic failure in children
24. Molecular adsorbent recycling system (MARS): Clinical results of a new membrane-based blood purification system for bioartificial liver support
25. MARS. A new treatment for hepatorenal failure. Molecular adsorbent and recirculating system
26. Use of MARS in the treatment of acute liver failure: Preliminary monocentric experience
27. Role of the molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure
28. Pathophysiology of cerebral edema in fulminant hepatic failure
29. Subclinical seizure activity and prophylactic phenytoin infusion in acute liver failure: A controlled clinical trial
30. Dissociated cerebral vasoparalysis in acute liver failure. A hypothesis of gradual cerebral hyperaemia
31. Complications ofintracranial pressure monitoring in fulminant hepatic failure
32. Recovery despite impaired cerebral perfusion in fulminant hepatic failure
33. Medical therapy of brain edema in fulminant hepatic failure
34. Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hepatic failure
35. Hepatectomy corrects cerebral hyperperfusion in fulminant hepatic failure
36. Controlled hyperventilation in the prevention of cerebral oedema in fulminant hepatic failure
37. Thiopental infusion in the treatment ofintracranial hypertension complicating fulminant hepatic failure
38. Hypothermia for fulminant hepatic failure: A cool approach to a burning problem
39. Moderate hypothermia for uncontrolled intracranial hypertension in acute liver failure
40. Hypothermia for the management ofintracranial hypertension in acute liver failure
41. Indomethacin in the management of elevated intracranial pressure: A review
42. Indomethacin normalizes intracranial pressure in acute liver failure: A twenty-three-year-old woman treated with indomethacin
43. Indomethacin prevents the development of experimental ammonia-induced brain edema in rats after portacaval anastomosis
44. Renal failure in acute liver failure
45. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis
46. Complications of cirrhosis II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem
47. Review article: Pharmacological treatment of the hepatorenal syndrome in cirrhotic patients
48. Current management and novel therapeutic strategies for refractory ascites and hepatorenal syndrome
49. Systemic, splanchnic and renal hemodynamic effects of a dopaminergic dose ofdopamine in patients with cirrhosis
50. Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome
51. Low-dose dopamine infusion in cirrhosis with refractory ascites
52. Terlipressin plus albumin infusion: An effective and safe therapy of hepatorenal syndrome
53. Hepatorenal syndrome in cirrhotic patients: Terlipressine is a safe and efficient treatment; propranolol and digitalic treatments: Precipitating and preventing factors?
54. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: A pilot study
55. Improvement in renal function in hepatorenal syndrome with N-acetylcysteine
56. Reversal of type 1 hepatorenal syndrome with the administration ofmidodrine and octreotide
57. Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patients
58. Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation
59. Treatment with terlipressin as a bridge to liver transplantation in a patient with hepatorenal syndrome
60. Changes in intracranial pressure during haemofiltration in oliguric patients with grade IV hepatic encephalopathy
61. Continuous vs. intermittent forms of haemofiltration and/or dialysis in the management of acute renal failure in patients with defective cerebral autoregulation at risk of cerebral oedema
62. Bacterial and fungal infection in acute liver failure
63. The systemic inflammatory response syndrome in acute liver failure
64. Prospective study comparing the efficacy of prophylactic parenteral antimicrobials, with or without enteral decontamination, in patients with acute liver failure
65. Administering granulocyte colony-stimulating factor to acute liver failure patients corrects neutrophil defects
66. Granulocyte colony-stimulating factor improves function of neutrophils from patients with acute liver failure
67. Soluble Fas and soluble Fas ligand levels in patients with acute hepatic failure
68. Essential roles of the Fas ligand in the development of hepatitis
69. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis
70. Bone marrow as a potential source of hepatic oval cells
71. Protein C replacement in severe meningococcemia: Rationale and clinical experience
72. Activated protein C prevents multiple organ injury following extensive hepatectomy in cirrhotic rats